

250 years of **EXCELLENCE**  
in medical education,  
research & innovation  
and healthcare


# Diabetes Mellitus in Family Practice

*Screening and management  
of diabetes mellitus in primary care*


**Dr. Bernadett Márkus**  
Assistant lecturer, General Practitioner

Department of Family Medicine,  
Semmelweis University  
2020

Semmelweis University | Faculty of Medicine  
<http://semmelweis.hu> | Department of Family Medicine



The latest edition of the IDF Diabetes Atlas shows that 463 million adults are currently living with diabetes. Diabetes is one of the fastest growing health challenges of the 21<sup>st</sup> century, with the number of adults living with diabetes having more than tripled over the past 20 years. <https://idf.org/>




Diabetes is rising worldwide... and is set to rise even further  
IDF estimates that there will be 578 million adults with diabetes by 2030, and 700 million by 2045.

<https://idf.org/>

Why is diabetes on the rise?

The increasing prevalence of diabetes worldwide is driven by a complex interplay of socioeconomic, demographic, environmental and genetic factors. The continued rise is largely due to an upsurge in type 2 diabetes and related risk factors, which include rising levels of obesity, unhealthy diets and widespread physical inactivity. However, levels of childhood-onset type 1 diabetes are also on the rise.

Growing urbanisation and changing lifestyle habits (e.g. higher calorie intake, increasing consumption of processed foods, sedentary lifestyles) are contributory factors for the increasing prevalence of type 2 diabetes at a societal level. While global prevalence of diabetes in urban areas is 10.8%, in rural areas it is lower, at 7.2%. However, this gap is closing, with rural prevalence on the rise.



<https://idf.org/>

<https://www.diabetesatlas.org/data/en/country/91/hu.html>

## Definition

Diabetes mellitus is characterized by **metabolic diseases that result in hyperglycemia.**

Diabetes mellitus is a **chronic disease** caused by inherited and/or acquired deficiency in production of insulin by the pancreas, or by the ineffectiveness of the insulin produced.

Such a deficiency results in increased concentrations of glucose in the blood, which in turn **damage many of the body's systems**, in particular the blood vessels and nerves.

(<https://www.who.int/mediacentre/factsheets/fs138/en/>)



Semmelweis University  
<http://semmelweis.hu>

Screening and management  
of diabetes mellitus in primary care

Dr. Bernádeti Márkus  
Assistant lecturer,  
General Practitioner

## Symptoms

The symptoms of diabetes may be pronounced, subdued, or even absent.

- In Type 1 diabetes, the **classic symptoms** are excessive secretion of urine (**polyuria**), thirst (**polydipsia**), **weight loss** (and **tiredness, slow wound healing**).
- These symptoms may be less marked in Type 2 diabetes. In this form, it can also happen that no early symptoms appear and the disease is only diagnosed several years after its onset, when complications are already present.



Semmelweis University  
<http://semmelweis.hu>

Screening and management  
of diabetes mellitus in primary care

Dr. Bernadett Márkus  
Assistant lecturer,  
General Practitioner

## Classification

Diabetes mellitus can be categorized into 4 classifications:

- Type 1 diabetes (T1D) mellitus
- Type 2 diabetes (T2D) mellitus
- Gestational diabetes mellitus (GDM)
- Diabetes mellitus due to other causes



Semmelweis University  
<http://semmelweis.hu>

Screening and management  
of diabetes mellitus in primary care

Dr. Bernádeti Márkus  
Assistant lecturer,  
General Practitioner

## Classification

- Diabetes mellitus due to other causes:  
monogenic diabetes syndromes (such as neonatal diabetes and maturity-onset diabetes of the young [MODY]),  
diseases of the exocrine pancreas (such as cystic fibrosis and pancreatitis),  
and drug- or chemical-induced diabetes (such as with glucocorticoid use, in the treatment of HIV/AIDS, or after organ transplantation)



Semmelweis University  
<http://semmelweis.hu>

Screening and management  
of diabetes mellitus in primary care

Dr. Bernadett Márkus  
Assistant lecturer,  
General Practitioner



## Type 1 Diabetes mellitus

**Plasma blood glucose** rather than A1C should be used to diagnose the acute onset of type 1 diabetes in individuals with symptoms of hyperglycemia.

**Screening** for type 1 diabetes risk with a panel of autoantibodies is currently recommended only in the setting of a research trial or in first-degree family members of a proband with type 1 diabetes.

Persistence of two or more autoantibodies predicts clinical diabetes and may serve as an indication for intervention in the setting of a clinical trial.

9

Standards of Medical Care in Diabetes - 2019. Diabetes Care 2019;42(Suppl. 1):S1-S2



Semmelweis University  
<http://semmelweis.hu>

Screening and management  
of diabetes mellitus in primary care

Dr. Bernádeti Márkus  
Assistant lecturer,  
General Practitioner

## Management of Type 1 DM

Management of Type 1 DM is done by an **endocrinologists/diabetologist.**

### **Role of Primary Care in Type 1 DM management:**

- Diagnosis
- Documentation
- Motivate and support the patient
- Treatment of comorbidities



Semmelweis University  
<http://semmelweis.hu>

Screening and management  
of diabetes mellitus in primary care

Dr. Bernadett Márkus  
Assistant lecturer,  
General Practitioner

## Gestational diabetes mellitus (GDM)

The rise in GDM and type 2 diabetes in parallel with obesity worldwide is of particular concern.

- **Specific risks of uncontrolled diabetes in pregnancy include:**

spontaneous abortion, preeclampsia, fetal demise, macrosomia, fetal anomalies, neonatal hypoglycemia and neonatal hyperbilirubinemia.



Semmelweis University  
<http://semmelweis.hu>

Screening and management  
of diabetes mellitus in primary care

Dr. Bernadett Márkus  
Assistant lecturer,  
General Practitioner

## Screening of GDM

### Screening during early pregnancy: 1st laboratory control

Preferred method: testing fasting plasma glucose or casual check

Diagnostic criteria:

- FPG  $\geq 7.0$  mmol/l and/or
- casual sample PG:  $\geq 11.1$  mmol/l

**Risk factors:** advanced age ( $\geq 35$  yrs.), overweight or obesity, excessive gestational weight gain, excessive central body fat deposition, family history of diabetes, short stature ( $< 1.50$  m), excessive fetal growth, polyhydramnios, hypertension or preeclampsia in the current pregnancy, history of recurrent miscarriage, offspring malformation, fetal or neonatal death, macrosomia, GDM during prior pregnancies and polycystic ovary syndrome.



Semmelweis University  
<http://semmelweis.hu>

Screening and management  
of diabetes mellitus in primary care

Dr. Bernádeti Márkus  
Assistant lecturer,  
General Practitioner

## If risk of GDM is increased

- During **16-18 pregnancy week**: 75 g Oral Glucose Tolerance Test (OGTT)
  - ↳ Gestational hyperglycemia:
    - ↳ FPG  $\geq 5.6$  mmol/l and/or
    - ↳ 2h PG:  $\geq 7.8$  mmol/l
- If risk is increased, but OGTT negative, repeat test during **24–28 pregnancy week**.
- **Postpartum OGTT: 6 weeks** after delivery to rule out impaired glucose tolerance (IGT)
- **Continued prolonged follow-up** is indicated to
  - ↳ offer and apply treatment in women with IGT designed to delay or prevent development of type 2 diabetes.
  - ↳ follow women with IFG or normal OGTT to detect later conversion to IGT or type 2 diabetes
  - ↳ identify diabetes for intensified treatment before a subsequent pregnancy to lower the risk of major congenital malformations in their infants.



Semmelweis University  
<http://semmelweis.hu>

Screening and management  
of diabetes mellitus in primary care

Dr. Bernadett Márkus  
Assistant lecturer,  
General Practitioner

## MANAGEMENT of Gestational Diabetes Mellitus (GDM)



Teamwork:  
General Practitioner  
Nurse  
Diabetologist  
Midwife  
Gynecologist



Semmelweis University  
<http://semmelweis.hu>

Screening and management  
of diabetes mellitus in primary care

Dr. Bernadett Márkus  
Assistant lecturer,  
General Practitioner

## Type 2 diabetes (T2D) mellitus

Non-communicable diseases (NCDs):  
CVD, diabetes, cancer, multi-skeletal disorders,  
neurological disorders, depression etc.  
are major cause of health problems in Europe.

Chronic diseases are largely preventable.



Semmelweis University  
<http://semmelweis.hu>

Screening and management  
of diabetes mellitus in primary care

Dr. Bernadett Márkus  
Assistant lecturer,  
General Practitioner

## Prevention

- Many of the health risks associated with **increasing body weight first appear in children and young people**.
- To help prevent type 2 diabetes and its complications, people of all ages should achieve and maintain **healthy body weight; be physically active, eat a healthy diet and avoid tobacco use** (smoking increases the risk of cardiovascular diseases).
- Individuals with impaired glucose tolerance **IGT**, or impaired fasting glycaemia **IFG** are in the intermediate stage between normality and diabetes and are at **high risk of developing type 2 diabetes**. This risk can be drastically reduced through **intensive lifestyle modification and pharmacological intervention**.
- **The public and private sectors** also have an important role to play in developing and implementing policies and programmes that **increase knowledge about diabetes, its prevalence and consequences, encourage and provide greater opportunities for greater physical activity, and improve the availability and accessibility of healthy foods**.



Semmelweis University  
<http://semmelweis.hu>

Screening and management  
of diabetes mellitus in primary care

Dr. Bernadett Márkus  
Assistant lecturer,  
General Practitioner



## Goals of the primary care



- The main goals of primary care is to screen and diagnose diabetes mellitus early
- In order to prevent and mitigate late complications
- Improve life expectancy and quality of life.



Semmelweis University  
<http://semmelweis.hu>

Screening and management  
of diabetes mellitus in primary care

Dr. Bernádeti Márkus  
Assistant lecturer,  
General Practitioner

## Criteria for testing for diabetes or prediabetes in asymptomatic adults

1. Testing should be considered in overweight or obese ( $BMI \geq 25 \text{ kg/m}^2$  or  $\geq 23 \text{ kg/m}^2$  in Asian Americans) adults who have one or more of the following risk factors:
  - First-degree relative with diabetes
  - High-risk race/ethnicity (e.g., African American, Latino, Native American, Asian American, Pacific Islander)
  - History of CVD
  - Hypertension ( $\geq 130/80 \text{ mmHg}$  or on therapy for hypertension)
  - HDL cholesterol level  $< 35 \text{ mg/dL}$  ( $0.90 \text{ mmol/L}$ ) and/or a triglyceride level  $> 250 \text{ mg/dL}$  ( $2.82 \text{ mmol/L}$ )
  - Women with polycystic ovary syndrome
  - Physical inactivity
  - Other clinical conditions associated with insulin resistance (e.g., severe obesity, acanthosis nigricans)
2. Patients with prediabetes ( $A1C \geq 5.7\%$  [ $39 \text{ mmol/mol}$ ], IGT, or IFG) should be tested yearly.
3. Women who were diagnosed with GDM should have lifelong testing at least every 3 years.
4. For all other patients, testing should begin at age 45 years.
5. If results are normal, testing should be repeated at a minimum of 3-year intervals, with consideration of more frequent testing depending on initial results and risk status.



Semmelweis University  
<http://semmelweis.hu>

Screening and management  
of diabetes mellitus in primary care

Dr. Bernadett Márkus  
Assistant lecturer,  
General Practitioner

Up to 50% of the people with T2D remain undiagnosed (and untreated) for a variable length of time and may develop complications during that period. Therefore, most guidelines recommend screening for T2D in people above 40 to 45 years of age and/or with high risk factors such as family history of diabetes, excess weight (obesity), abdominal obesity (increased waist circumference) and hypertension.

# FINDRISC

FINDRISC	Risk	10-year risk of developing T2DM	
		Men	Women
0-3	Very low	0.3%	0.1%
4-8	Low	0.8%	0.4%
9-12	Moderate	2.6%	2.2%
13-20	High	23.1%	14.1%
>21	Very high	~50%	~50%

Hungary: >12 points OGTT

Finnish Diabetes Association

### TYPE 2 DIABETES RISK ASSESSMENT FORM

Circle the right alternative and add up your points.

**1. Age**

0.a. Under 45 years  
2.a. 45-54 years  
3.a. 55-64 years  
4.a. Over 64 years

**2. Body mass index**  
(See reverse of form)

0.a. Lower than 25 kg/m<sup>2</sup>  
1.a. 25-30 kg/m<sup>2</sup>  
2.a. Higher than 30 kg/m<sup>2</sup>

**3. Waist circumference measured below the ribs**  
(usually at the level of the navel)

<b>MEN</b>	<b>WOMEN</b>
0.a. Less than 94 cm	0.a. Less than 80 cm
1.a. 94-102 cm	1.a. 80-88 cm
2.a. More than 102 cm	2.a. More than 88 cm

**4. Have you ever taken medication for high blood pressure on regular basis?**

0.a. No  
2.a. Yes

**5. Have you ever been found to have high blood glucose (eg in a health examination, during an illness, during pregnancy)?**

0.a. No  
2.a. Yes

**6. Have any of the members of your immediate family or other relatives been diagnosed with diabetes (type 1 or type 2)?**

0.a. No  
2.a. Yes (grandparent, aunt, uncle or first cousin (2nd or 3rd degree), brother, sister or child)

**7. No parent, brother, sister or your child**

0.a. No  
2.a. Yes

**4. Do you usually have daily at least 30 minutes of physical activity at work and/or during leisure time (including normal daily activity)?**

0.a. No  
2.a. Yes

**5. How often do you eat vegetables, fruit or berries?**

0.a. Every day  
2.a. Not every day

**Total Risk Score**

0-3 The risk of developing type 2 diabetes within 10 years is

Lower than 7	Low estimated 1 in 100 will develop disease
7-11	Slightly elevated estimated 1 in 25 will develop disease
12-14	Moderate estimated 1 in 8 will develop disease
15-20	High estimated 1 in 3 will develop disease
Higher than 20	Very high estimated 1 in 2 will develop disease

Please turn over

This test is used in primary care in Hungary to evaluate risk factors. There are differences in the screening tool. Ideally screening should not include blood tests because one of its purpose is to reduce the number of people needing a laboratory test. Screening questionnaires are becoming widely used because they include the main risk factors and can be easily performed by trained personnel and even by the subject being screened. One such tool is the FINDRISC, which is an 8-item questionnaire that provides a measure of the probability of developing T2D over the following 10 years.

## Criteria defining prediabetes

FPG 100 mg/dL (5.6 mmol/L) to 125 mg/dL (6.9 mmol/L) (IFG)

OR

2-h PG during 75-g OGTT 140 mg/dL (7.8 mmol/L) to 199 mg/dL (11.0 mmol/L) (IGT)

OR

A1C 5.7–6.4% (39–47 mmol/mol)

For all three tests, risk is continuous, extending below the lower limit of the range and becoming disproportionately greater at the higher end of the range.



Semmelweis University  
<http://semmelweis.hu>

Screening and management  
of diabetes mellitus in primary care

Dr. Bernadett Márkus  
Assistant lecturer,  
General Practitioner

FPG: fasting plasma glucose.

IFG: impaired fasting glucose.

PG: plasma glucose.

OGTT: oral glucose tolerance test

IGT: impaired glucose tolerance

A1C: glycated haemoglobin (A1c)

## Criteria for the diagnosis of diabetes

FPG  $\geq$ 126 mg/dL (7.0 mmol/L).

Fasting is defined as no caloric intake for at least 8 h.\*

OR

2-h PG  $\geq$ 200 mg/dL (11.1 mmol/L) during OGTT.

The test should be performed as described by the WHO, using a glucose load containing the equivalent of 75-g anhydrous glucose dissolved in water.\*

OR

A1C  $\geq$ 6.5% (48 mmol/mol).

The test should be performed in a laboratory using a method that is NGSP certified and standardized to the DCCT assay.\*

OR

In a patient with classic symptoms of hyperglycemia or hyperglycemic crisis, a random plasma glucose  $\geq$ 200 mg/dL (11.1 mmol/L).

\* In the absence of unequivocal hyperglycemia, diagnosis requires two abnormal test results from the same sample or in two separate test samples.



Semmelweis University  
<http://semmelweis.hu>

Screening and management  
of diabetes mellitus in primary care

Dr. Bernadett Márkus  
Assistant Lecturer,  
General Practitioner

The purpose of the NGSP is to standardize Hemoglobin A1c test results to those of the Diabetes Control and Complications Trial (DCCT) and United Kingdom Prospective Diabetes Study (UKPDS) which established the direct relationships between HbA1c levels and outcome risks in patients with diabetes.

<http://www.ngsp.org/>

FPG: fasting plasma glucose.

IFG: impaired fasting glucose.

PG: plasma glucose.

OGTT: oral glucose tolerance test

IGT: impaired glucose tolerance

A1C: glycated haemoglobin (A1c)

## Tasks of primary care recognition of type 2 DM

### Assess key patient characteristics:

current lifestyle, comorbidities,  
clinical characteristics, current medications

### Physical examination:

- ↳ BMI, waist-to-hip,
- ↳ Foot examination (deformations, ulcerations, vascular assessment)
- ↳ Assessment for distal symmetric polyneuropathy (temperature, pinprick, vibration, 10-g monofilament testing)
- ↳ Assessment of peripheral vascular status (pulse inspection, Doppler, ankle-brachial index [normal range: 0.91-1.39])



Semmelweis University  
<http://semmelweis.hu>

Screening and management  
of diabetes mellitus in primary care

Dr. Bernadett Márkus  
Assistant lecturer,  
General Practitioner

## Tasks of primary care recognition of type 2 DM

- Blood pressure measurement (during sitting, standing), ABPM
- ECG (normally R-R time decrease during inspiration)
- Laboratory:
  - FPG & PPG
  - HbA1c
  - Lipids
  - Kidney functions (creatinine, eGFR, blood urea nitrogen)
  - Urine test (ketones, sediment, sugar, albumin)
- Cardio-metabolic risk assessment
- Refer for ocular fundus exam
- Begin patient engagement in the formulation of a care management plan, initiate treatment.

*According to current regulation in Hungary, primary care is entitled only to prescribe Metformin for Type 2 DM patients. All other reimbursed DM drugs are to be prescribed by an endocrinologist or internist.*



Semmelweis University  
<http://semmelweis.hu>

Screening and management  
of diabetes mellitus in primary care

Dr. Bernádeti Márkus  
Assistant lecturer,  
General Practitioner

According to current regulation in Hungary, primary care is entitled only to prescribe Metformin for Type 2 DM patients.  
All other reimbursed DM drugs are to be prescribed by an endocrinologist or internist.

# Management of diabetes

## ROLE OF THE PRIMARY CARE



## SELF-MANAGEMENT OF THE PATIENT



Semmelweis University  
<http://semmelweis.hu>

Screening and management  
of diabetes mellitus in primary care

Dr. Bernádeti Márkus  
Assistant lecturer,  
General Practitioner



## Lifestyle management

- All people with type 2 diabetes should be offered access to ongoing **DSMES - Diabetes self-management education and support programmes**.
- Facilitating **medication adherence** should be specifically considered when selecting glucose-lowering medications.
- An individualised programme of MNT- **Medical nutrition therapy** should be offered to all patients
- **All overweight and obese patients with diabetes should be advised** of the health benefits of weight loss and encouraged to engage in a programme of intensive lifestyle management, which may include food substitution.
- **Increasing physical activity** improves glycaemic control and should be encouraged in all people with type 2 diabetes.



Semmelweis University  
<http://semmelweis.hu>

Screening and management  
of diabetes mellitus in primary care

Dr. Bernadett Márkus  
Assistant lecturer,  
General Practitioner

## DECISION CYCLE FOR PATIENT-CENTRED GLYCAEMIC MANAGEMENT IN TYPE 2 DIABETES




Fig. 1 Decision cycle for patient-centred glycaemic management in type 2 diabetes



Semmelweis University  
<http://semmelweis.hu>

Screening and management  
of diabetes mellitus in primary care

Dr. Bernadett Márkus  
Assistant Lecturer,  
General Practitioner

## Annual lab control type 2 DM

- ↻ HbA1c – (every 3 months)
- ↻ FPG & PPG (OGTT)
- ↻ Se Cholesterol,
- ↻ HDL-cholesterol,
- ↻ LDL-cholesterol
- ↻ Triglyceride
- ↻ Creatinine
- ↻ eGFR
- ↻ Urine sugar, ketones, sediment
- ↻ Urine culture (if needed)
- ↻ Quantitative albumin measurement (24h urine sample or Albumin to Creatinine Ratio).



Semmelweis University  
<http://semmelweis.hu>

Screening and management  
of diabetes mellitus in primary care

Dr. Bernádeti Márkus  
Assistant lecturer,  
General Practitioner

## Annual control type 2 DM

Control of the complications, comorbidities  
Control of the self-management



Semmelweis University  
<http://semmelweis.hu>

Screening and management  
of diabetes mellitus in primary care

Dr. Bernádeti Márkus  
Assistant lecturer,  
General Practitioner

## METABOLIC TARGETS

- ↪ Fasting plasma glucose (FPG):  $\leq 6.0$  mmol/l
- ↪ Post prandial plasma glucose (PPG):  $< 7.5$  mmol/l
- ↪ HbA1c  $< 7\%$  (target range: 6.0 - 8.0%, should be personalized)
- ↪ Blood pressure:  $< 130/80$  Hgmm
  - ↳ In case of albuminuria:  $< 130$  Hgmm systolic BP
- ↪ Lipids: according to cardiovascular risk
- ↪ Target BMI and waist to hip ratio

*Proper metabolic control help prevent serious complications that can arise from diabetes.*



Semmelweis University  
<http://semmelweis.hu>

Screening and management  
of diabetes mellitus in primary care

Dr. Bernadett Márkus  
Assistant lecturer,  
General Practitioner

*Proper metabolic control help prevent serious complications that can arise from diabetes.*

# Treatment TARGETS

**Table 9** Summary of treatment targets for the management of patients with diabetes

Risk factor	Target
BP	<ul style="list-style-type: none"> <li>Target SBP 130 mmHg for most adults, &lt;130 mmHg if tolerated, but not &lt;120 mmHg</li> <li>Less stringent targets, SBP 130–139 in older patients (aged &gt;65 years)</li> </ul>
Glycaemic control HbA1c	<ul style="list-style-type: none"> <li>HbA1c target for most adults is &lt;7.0% (&lt;53 mmol/mol)</li> <li>More stringent HbA1c goals of &lt;6.5% (48 mmol/mol) may be suggested on a personalized basis if this can be achieved without significant hypoglycaemia or other adverse effects of treatment</li> <li>Less stringent HbA1c goals of &lt;8% (64 mmol/mol) or &lt;9% (75 mmol/mol) may be adequate for elderly patients (see section 6.2.1)</li> </ul>
Lipid profile: LDL-C	<ul style="list-style-type: none"> <li>In patients with DM at very high CV risk,<sup>a</sup> target LDL-C to &lt;1.4 mmol/L (&lt;55 mg/dL)</li> <li>In patients with DM at high risk,<sup>a</sup> target LDL-C to &lt;1.8 mmol/L (&lt;70 mg/dL)</li> <li>In patients with DM at moderate CV risk,<sup>a</sup> aim for an LDL-C target of &lt;2.5 mmol/L (&lt;100 mg/dL)</li> </ul>
Platelet inhibition	In DM patients at high/very high CV risk
Smoking	Cessation obligatory
Physical activity	Moderate to vigorous, ≥150 min/week, combined aerobic and resistance training
Weight	Aim for weight stabilization in overweight or obese patients with DM, based on calorie balance, and weight reduction in subjects with IGT, to prevent the development of DM.
Dietary habits	Reduction of caloric intake is recommended in obese patients with T2DM to lower body weight; there is no ideal percentage of calories from carbohydrate, protein, and fat for all people with DM.

BP = blood pressure; CV = cardiovascular; DM = diabetes mellitus; HbA1c = haemoglobin A1c; IGT = impaired glucose tolerance; LDL-C = low-density lipoprotein cholesterol; SBP = systolic blood pressure; T2DM = type 2 diabetes mellitus.

<sup>a</sup>See Table 7.



Semmelweis University  
<http://semmelweis.hu>

Screening and management  
of diabetes mellitus in primary care

Dr. Bernadett Márkus  
Assistant Lecturer,  
General Practitioner

Patient self-management is an important part of successfully preventing or delaying diabetes complications.



Semmelweis University  
<http://semmelweis.hu>

Screening and management  
of diabetes mellitus in primary care

Dr. Bernadett Márkus  
Assistant lecturer,  
General Practitioner

## Glucose-lowering treatments

Lifestyle management, including medical nutrition therapy, physical activity, weight loss, counselling for smoking cessation, and psychological support, often delivered in the context of diabetes self-management education and support (DSMES), are fundamental aspects of diabetes care.

The expanding number of glucose-lowering treatments – from behavioural interventions to medications and surgery – and growing information about their benefits and risks provides more options for people with diabetes and providers, but can complicate decision making.



Semmelweis University  
<http://semmelweis.hu>

Screening and management  
of diabetes mellitus in primary care

Dr. Bernadett Márkus  
Assistant lecturer,  
General Practitioner



## Treatment – Glucose lowering medication

- The aim of blood glucose lowering management is to reduce long-term complications of diabetes.
- Good glycaemic management yields substantial and enduring reductions in onset and progression of microvascular complications.
- The benefits of intensive glucose control emerge slowly, while the harms can be immediate, people with longer life expectancy have more to gain from intensive glucose control.



Semmelweis University  
<http://semmelweis.hu>

Screening and management  
of diabetes mellitus in primary care

Dr. Bernadett Márkus  
Assistant Lecturer,  
General Practitioner

DSMES Diabetes self-management education and support

## Treatment – Glucose lowering medication

Glycaemic treatment targets should be individualised based on patient preferences and goals, risk of adverse effects of therapy (e.g. hypoglycaemia and weight gain) and patient characteristics, including frailty and comorbid conditions, polypharmacy and cost .

Efficacy in reducing hyperglycaemia, along with tolerability and safety were primary factors in glucose-lowering medication selection.




Semmelweis University  
<http://semmelweis.hu>

Screening and management  
of diabetes mellitus in primary care

Dr. Bernadett Márkus  
Assistant lecturer,  
General Practitioner


DSMES Diabetes self-management education and support





The major change from prior consensus reports is based on new evidence that specific sodium–glucose cotransporter-2 (SGLT2) inhibitors or glucagon-likepeptide-1(GLP-1) receptor agonists improve cardiovascular outcomes, as well as secondary outcomes such as HF and progression of renal disease, in patients with established CVD or CKD.

## Treatment algorithm in patients with type 2 DM



Semmelweis University  
<http://semmelweis.hu>

Screening and management  
of diabetes mellitus in primary care

Dr. Bernadett Márkus  
Assistant Lecturer,  
General Practitioner

Therefore, an important early step in this new approach is to consider the presence or absence of ASCVD, HF and CKD, conditions in aggregate affecting 15–25% of the population with type 2 diabetes.

## Consensus recommendations ADA, EASD


- Among patients with type 2 diabetes who have established ASCVD, SGLT2 inhibitors or GLP-1 receptor agonists with proven cardiovascular benefit are recommended as part of glycaemic management.
- Among patients with ASCVD in whom HF coexists or is of special concern, SGLT2 inhibitors are recommended
- For patients with type 2 diabetes and CKD, with or without CVD, consider the use of an SGLT2 inhibitor shown to reduce CKD progression or, if contraindicated or not preferred, a GLP-1 receptor agonist shown to reduce CKD progression



Semmelweis University  
<http://semmelweis.hu>

Screening and management  
of diabetes mellitus in primary care

Dr. Bernadett Márkus  
Assistant lecturer,  
General Practitioner



Semmelweis University  
<http://semmelweis.hu>

Screening and management  
 of diabetes mellitus in primary care

Dr. Bernadett Márkus  
 Assistant lecturer,  
 General Practitioner

## Atherosclerotic cardiovascular disease

Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of death in people with type 2 diabetes.

Diabetes confers substantial independent ASCVD risk, and most people with type 2 diabetes have additional risk factors such as hypertension, dyslipidaemia, obesity, physical inactivity, chronic kidney disease (CKD) and smoking.



Semmelweis University  
<http://semmelweis.hu>

Screening and management  
of diabetes mellitus in primary care

Dr. Bernadett Márkus  
Assistant lecturer,  
General Practitioner



## Cardiovascular risk categories

<b>Very high risk</b>	Patients with DM <b>and</b> established CVD <b>or</b> other target organ damage <sup>b</sup> <b>or</b> three or more major risk factors <sup>c</sup> <b>or</b> early onset T1DM of long duration (>20 years)
<b>High risk</b>	Patients with DM duration ≥10 years without target organ damage plus any other additional risk factor
<b>Moderate risk</b>	Young patients (T1DM aged <35 years or T2DM aged <50 years) with DM duration <10 years, without other risk factors

© ESC 2019

CV = cardiovascular; CVD = cardiovascular disease; DM = diabetes mellitus; T1DM = type 1 diabetes mellitus; T2DM = type 2 diabetes mellitus.

<sup>a</sup>Modified from the 2016 European Guidelines on cardiovascular disease prevention in clinical practice.<sup>27</sup>

<sup>b</sup>Proteinuria, renal impairment defined as eGFR <30 ml/min/1.73 m<sup>2</sup>, left ventricular hypertrophy, or retinopathy.

<sup>c</sup>Age, hypertension, dyslipidemia, smoking, obesity.



Semmelweis University  
<http://semmelweis.hu>

Screening and management  
of diabetes mellitus in primary care

Dr. Bernadett Márkus  
Assistant lecturer,  
General Practitioner

## PREVENTION OF COMPLICATIONS

- ↳ How to prevent or delay the onset of complications?
- ↳ Which complications can we screen?
- ↳ When to screen?
- ↳ How to screen?
  
- ↳ How to manage those complications which we were able to test?



Semmelweis University  
<http://semmelweis.hu>

Screening and management  
of diabetes mellitus in primary care

Dr. Bernádeti Márkus  
Assistant lecturer,  
General Practitioner

## Acute and chronic (late) complications

### Acute complications:

- Hypoglycemia
- Diabetic Ketoacidosis (DKA)
- Hyperosmolar Hyperglycemic Syndrome (HHS)
- Metformin Associated Lactic Acidosis (MALT)

### Late complications:

#### Microvascular

- ↳ Retinopathy
- ↳ Nephropathy
- ↳ Neuropathy

#### Macrovascular

- ↳ coronary heart disease
- ↳ cerebrovascular disease
- ↳ peripheral arterial disease




Semmelweis University  
<http://semmelweis.hu>

Screening and management  
of diabetes mellitus in primary care

Dr. Bernadett Márkus  
Assistant lecturer,  
General Practitioner

## LATE complications at the time of diagnosis of DM



1. Wingard DL et al. *Diabetes Care* 1993; 16: 1022-5.  
2. UKPDS Group. *Diabetes Res* 1990; 13: 1-11.



Semmelweis University  
<http://semmelweis.hu>

Screening and management  
of diabetes mellitus in primary care

Dr. Bernádeti Márkus  
Assistant lecturer,  
General Practitioner

# Complications

People with diabetes are at **higher risk** of developing periodontal disease

Diabetic retinopathy affects over **one-third** of all people with diabetes and is the leading cause of vision loss in working-age adults

Pregnant women with diabetes or at high risk for GDM should manage their glycaemia throughout their pregnancy to avoid long-term consequences for themselves and their children, and **transgenerational effects** (higher risk of obesity, diabetes, hypertension and kidney disease in the offspring)

People with diabetes are **2 to 3 times** more likely to have cardiovascular disease (CVD)

The prevalence of end-stage renal disease (ESRD) is up to **10 times higher** in people with diabetes

Every **30 seconds** a lower limb or part of a lower limb is lost to amputation somewhere in the world as a consequence of diabetes



Semmelweis University  
<http://semmelweis.hu>

Screening and management  
of diabetes mellitus in primary care

Dr. Bernádeti Márkus  
Assistant lecturer,  
General Practitioner

## PREVENTION OF COMPLICATIONS

- ↪ Which complications can we screen?
- ↪ When to screen?
- ↪ How to screen?
  
- ↪ How to manage those complications which we were able to test?



Semmelweis University  
<http://semmelweis.hu>

Screening and management  
of diabetes mellitus in primary care

Dr. Bernádeti Márkus  
Assistant lecturer,  
General Practitioner

## Screening of Diabetic Retinopathy

### Role of primary care:

refer all diabetic patients for *annual* eye examination.



**Optimize glycemic control** to reduce the risk or slow the progression of diabetic retinopathy.

**Optimize blood pressure and serum lipid control** to reduce the risk or slow the progression of diabetic retinopathy.

Patients with type 2 diabetes should have **an initial dilated and comprehensive eye examination**.

Women with preexisting type 1 or type 2 diabetes who are **planning pregnancy or who are pregnant** should be counseled on the risk of development and/or progression of diabetic retinopathy.

Eye examinations should occur before pregnancy or in the first trimester. Patients should be monitored every trimester and for 1-year postpartum.



Semmelweis University  
<http://semmelweis.hu>

Screening and management  
of diabetes mellitus in primary care

Dr. Bernadett Márkus  
Assistant lecturer,  
General Practitioner

## Screening of Chronic Kidney Disease / Diabetic nephropathy

### Screening

- ↪ At least once a year, assess urinary albumin (e.g., spot urinary albumin-to-creatinine ratio) and eGFR
- ↪ in patients with type 1 diabetes with duration of  $\geq 5$  years,
- ↪ in all patients with type 2 diabetes,
- ↪ and in all patients with comorbid hypertension.

### Treatment

- ↪ Optimize glucose control
- ↪ Optimize blood pressure control (RAAS)
- ↪ Dietary protein intake should be approximately 0.8 g/kg body weight per day



Semmelweis University  
<http://semmelweis.hu>

Screening and management  
of diabetes mellitus in primary care

Dr. Bernadett Márkus  
Assistant lecturer,  
General Practitioner



# Screening of CKD /Stages

GFR and ACR categories and risk of adverse outcomes			ACR categories (mg/mmol), description and range			
			<3 Normal to mildly increased	3-30 Moderately increased	>30 Severely increased	
			A1	A2	A3	
GFR categories (ml/min/1.73m <sup>2</sup> ), description and range	≥90 Normal and high	G1	Green	Yellow	Orange	Increasing risk ↓
	60-89 Mild reduction related to normal range for a young adult	G2	Green	Yellow	Orange	
	45-59 Mild-moderate reduction	G3a	Yellow	Orange	Red	
	30-44 Moderate-severe reduction	G3b	Orange	Red	Red	
	15-29 Severe reduction	G4	Red	Red	Red	
<15 Kidney failure	G5	Red	Red	Red		

- Patients with CKD can be classified depending on their level of kidney function, or eGFR, and the amount of protein present in the urine.
- This information forms the basis of CKD staging which is useful for planning follow up and management.
- The higher the stage (G1->G5) and the greater the amount of protein present in the urine (A1->A3) the more "severe" the CKD.



Semmelweis University  
<http://semmelweis.hu>

Screening and management  
of diabetes mellitus in primary care

Dr. Bernadett Márkus  
Assistant Lecturer,  
General Practitioner

## CKD MONITORING

- When eGFR is  $<60$  mL/min/1.73 m<sup>2</sup>, evaluate and manage potential complications of CKD.
- Patients should be referred for evaluation for renal replacement treatment if they have an eGFR  $<30$  mL/min/1.73 m<sup>2</sup>.
- Promptly refer to a physician experienced in the care of kidney disease for uncertainty about the etiology of kidney disease, difficult management issues, and rapidly progressing kidney disease (signs of chronic pyelonephritis, hematuria 2 times or more, nephrotic patient, anemia, secondary hyperparathyroidism, metabolic bone disease, resistant hypertension, or electrolyte disturbances).




Semmelweis University  
<http://semmelweis.hu>

Screening and management  
of diabetes mellitus in primary care

Dr. Bernadett Márkus  
Assistant lecturer,  
General Practitioner

# DIABETIC NEUROPATHY



Semmelweis University  
<http://semmelweis.hu>

Screening and management  
of diabetes mellitus in primary care

Dr. Bernadett Márkus  
Assistant lecturer,  
General Practitioner

## DIABETIC NEUROPATHY

- All patients should be assessed for diabetic peripheral neuropathy **starting at diagnosis of type 2 diabetes** and 5 years after the diagnosis of type 1 diabetes and at least annually thereafter.
- Assessment for **distal symmetric polyneuropathy** should include a careful history and assessment of either temperature or pinprick sensation (small-fiber function) and vibration sensation using a 128-Hz tuning fork (for large fiber function).
- All patients should have annual 10-g monofilament testing to identify feet at risk for ulceration and amputation.
- **Up to 50% of diabetic peripheral neuropathy (DPN) may be asymptomatic.**

If not recognized and if preventive foot care is not implemented, patients are at risk for injuries to their insensate feet.



Semmelweis University  
<http://semmelweis.hu>

Screening and management  
of diabetes mellitus in primary care

Dr. Bernadett Márkus  
Assistant lecturer,  
General Practitioner

## DIABETIC NEUROPATHY

**Distal symmetric polyneuropathy (DSPN):**  
75% of diabetic neuropathies.

Diabetic autonomic neuropathies: In type 2 diabetes, the prevalence of CAN also increases with diabetes duration and may be present in up to 60% of patients with type 2 diabetes after 15 years

Other, atypical forms



Semmelweis University  
<http://semmelweis.hu>

Screening and management  
of diabetes mellitus in primary care

Dr. Bernadett Márkus  
Assistant lecturer,  
General Practitioner

## Symptoms and signs of DSPN

	Large myelinated nerve fibers	Small myelinated nerve fibers
Function	Pressure, balance	Nociception, protective sensation
Symptoms	Numbness, tingling, poor balance	Pain, burning, electric shocks, stabbing
Examination (clinically diagnostic)	Ankle reflexes: reduced/absent Vibration perception: reduced/absent 10-g monofilament: reduced/absent Proprioception: reduced/absent	Thermal (cold/hot) discrimination: reduced/absent Pinprick sensation: reduced/absent

Diabetic Neuropathy: A Position Statement by the American Diabetes Association. Diabetes Care 2017 Jan; 40(1): 136-154.



Semmelweis University  
<http://semmelweis.hu>

Screening and management  
of diabetes mellitus in primary care

Dr. Bernádeti Márkus  
Assistant Lecturer,  
General Practitioner

## Symptoms and signs associated with diabetic autonomic neuropathy

Cardiovascular AN	Gastrointestinal	Urogenital	Sudomotor
Resting tachycardia	Gastroparesis (Gastropathy)	Bladder dysfunction	Dry skin
Abnormal blood pressure regulation	Nausea Bloating Loss of appetite Postprandial vomiting	Frequency, urgency Nocturia Hesitancy Weak stream Incontinence	Anhidrosis Gustatory sweating
Orthostatic hypotension	Esophageal dysfunction	Sexual dysfunction	
Orthostatic tachycardia or bradycardia and chronotropic incompetence	Diabetic diarrhea		



Semmelweis University  
<http://semmelweis.hu>

Screening and management  
of diabetes mellitus in primary care

Dr. Bernádeti Márkus  
Assistant lecturer,  
General Practitioner

## FOOT CARE

Perform a comprehensive **foot evaluation at least annually to identify risk factors for ulcers and amputations.**

Patients with evidence of sensory loss or prior ulceration or amputation should have their **feet inspected at every visit.**

The examination should include **inspection of the skin, assessment of foot deformities, neurological assessment** (10-g monofilament testing with at least one other assessment: pinprick, temperature, vibration), and **vascular assessment including pulses in the legs and feet.**

Patients with symptoms of claudication or decreased or absent pedal pulses should be referred for ankle-brachial index and for further vascular assessment as appropriate.



Semmelweis University  
<http://semmelweis.hu>

Screening and management  
of diabetes mellitus in primary care

Dr. Bernadett Márkus  
Assistant Lecturer,  
General Practitioner



## Hypertension/Blood Pressure Control

Blood pressure should be measured at **every routine clinical visit**.

- ↪ Patients found to have elevated blood pressure ( **$\geq 130/80$  mmHg**) should have blood pressure confirmed using multiple readings.
- ↪ For individuals with diabetes and hypertension at **higher cardiovascular risk** (existing ASCVD or 10-year ASCVD risk  $>15\%$ ), a blood pressure target of  **$<130/80$  mmHg** may be appropriate, if it can be safely attained.



Semmelweis University  
<http://semmelweis.hu>

Screening and management  
of diabetes mellitus in primary care

Dr. Bernadett Márkus  
Assistant Lecturer,  
General Practitioner

## Hypertension/Blood Pressure Control

Change in recommendations	
2013	2019
<b>BP targets</b>	
BP target <140/85 mmHg for all	Individualized BP targets are recommended SBP to 130 mmHg and, if well tolerated, <130 mmHg, but not <120 mmHg In older people (>65 years) target SBP to a range of 130 - 139 mmHg DBP to <80 mmHg but not <70 mmHg On-treatment SBP to <130 mmHg should be considered for patients at high risk of cerebrovascular events or diabetic kidney disease.



Semmelweis University  
<http://semmelweis.hu>

Screening and management  
of diabetes mellitus in primary care

Dr. Bernádeti Márkus  
Assistant Lecturer,  
General Practitioner

## Blood pressure

### Key messages

- The BP goal is to target systolic BP (SBP) to 130 mmHg in patients with DM and <130 mmHg if tolerated, but not <120 mmHg. In older people (aged >65 years), the SBP goal is to a range of 130-139 mmHg.
- The diastolic BP (DBP) target is <80 mmHg, but not <70 mmHg.
- Optimal BP control reduces the risk of micro- and macrovascular complications.
- Guidance on lifestyle changes must be provided for patients with DM and hypertension.
- Evidence strongly supports the inclusion of an angiotensin-converting enzyme inhibitor (ACEI), or an angiotensin receptor blocker (ARB) in patients who are intolerant to ACEI.
- BP control often requires multiple drug therapy with a renin-angiotensin-aldosterone system (RAAS) blocker, and a calcium channel blocker or diuretic. Dual therapy is recommended as first-line treatment.
- The combination of an ACEI and an ARB is not recommended.
- In pre-DM, the risk of new-onset DM is lower with RAAS blockers than with beta-blockers or diuretics.
- Patients with DM on combined antihypertensive treatments should be encouraged to self-monitor BP.



Semmelweis University  
<http://semmelweis.hu>

Screening and management  
of diabetes mellitus in primary care

Dr. Bernadett Márkus  
Assistant Lecturer,  
General Practitioner

## Cardiovascular risk categories

<b>Very high risk</b>	Patients with DM <b>and</b> established CVD <b>or</b> other target organ damage <sup>b</sup> <b>or</b> three or more major risk factors <sup>c</sup> <b>or</b> early onset T1DM of long duration (>20 years)
<b>High risk</b>	Patients with DM duration ≥10 years without target organ damage plus any other additional risk factor
<b>Moderate risk</b>	Young patients (T1DM aged <35 years or T2DM aged <50 years) with DM duration <10 years, without other risk factors

© ESC 2019

CV = cardiovascular; CVD = cardiovascular disease; DM = diabetes mellitus; T1DM = type 1 diabetes mellitus; T2DM = type 2 diabetes mellitus.

<sup>a</sup>Modified from the 2016 European Guidelines on cardiovascular disease prevention in clinical practice.<sup>27</sup>

<sup>b</sup>Proteinuria, renal impairment defined as eGFR <30 ml/min/1.73 m<sup>2</sup>, left ventricular hypertrophy, or retinopathy.

<sup>c</sup>Age, hypertension, dyslipidemia, smoking, obesity.



Semmelweis University  
<http://semmelweis.hu>

Screening and management  
of diabetes mellitus in primary care

Dr. Bernadett Márkus  
Assistant lecturer,  
General Practitioner

## Lipid management

In patient with T2DM **at moderate CV risk**,  
an **LDL-C target of <2.5 mmol/l** (<100 mg/dl) is  
recommended

In patient with T2DM **at high CV risk**,  
an **LDL-C target of <1.8 mmol/l** (<70 mg/dl) is  
recommended


In patient with T2DM **at very high CV risk**,  
an **LDL-C target of <1.4 mmol/l** (<55 mg/dl) is  
recommended





Semmelweis University  
<http://semmelweis.hu>

Screening and management  
of diabetes mellitus in primary care

Dr. Bernadett Márkus  
Assistant lecturer,  
General Practitioner



**"People with diabetes, can live healthy and fulfilling lives with the provision of an uninterrupted supply of insulin and blood glucose testing equipment, when combined with a healthy lifestyle"**

  Semmelweis University  
<http://semmelweis.hu>

Screening and management of diabetes mellitus in primary care

Dr. Bernádeti Márkus  
Assistant lecturer,  
General Practitioner

European Association for the Study of Diabetes (EASD)/ e-learning courses  
<https://www.easd.org/education/easd-e-learning.html>

EASD e-Learning

Courses

### Diabetes e-Learning by EASD

EASD has a long and proud history of postgraduate education and the organisation is delighted now to be able to offer online learning as part of this. We are building a suite of e-learning modules designed to educate, inform and engage healthcare professionals around the world.

The wide range of diabetes modules that will populate this platform have been designed with international experts in the field and they use innovative multimedia and challenging knowledge checks to help you to learn more about this fast-moving area.

[Watch your next account](#)

Semmelweis University  
<http://semmelweis.hu>

Screening and management of diabetes mellitus in primary care

Dr. Bernadett Márkus  
Assistant Lecturer,  
General Practitioner

The European Association for the Study of Diabetes e.V. (EASD) is a non-profit, medical scientific association. It was founded in 1965 and its headquarters is based in Duesseldorf, Germany. The aims of the Association are to encourage and support research in the field of diabetes, the rapid diffusion of acquired knowledge and to facilitate its application.  
<https://www.easd.org/>

# EASD e-learning courses

Sign In / Register to enroll

### Diagnosis of type 1 diabetes

This course has been developed to introduce you to the diagnosis of type 1 diabetes and to explore the possible causes of the condition.

NUMBER OF WEEKS: 2

TOPIC: **ANTHROPOLOGY** | **ETIOLOGY**

SUBTOPIC: **DIAGNOSIS** | **PREVENTION** | **MANAGEMENT** | **TYPE 1**

ESTIMATED TIME TO COMPLETE: 1 hr

VIEW COURSE

Sign In / Register to enroll

### Cardiovascular health and diabetes

This course focuses on cardiovascular health - one of the most significant and challenging aspects of care for type 1 and type 2 diabetes.

NUMBER OF WEEKS: 2

TOPIC: **CARDIOVASCULAR DISEASE** | **COMPLICATIONS**

SUBTOPIC: **OP & PREVENTION** | **GLYCAEMIC CONTROL**

ESTIMATED TIME TO COMPLETE: 1 hr

VIEW COURSE

Sign In / Register to enroll

### The diabetic foot

This course gives you an overview of diabetic foot disease, while exploring in detail some of the common characteristics and difficulties this important but sometimes neglected complication of diabetes can give rise to.

NUMBER OF WEEKS: 2

TOPIC: **COMPLICATIONS** | **DIABETIC FOOT**

SUBTOPIC: **DIAGNOSIS** | **PREVENTION** | **RESEARCH**

SUBTOPIC: **NEUROPATHY** | **ULCERATION**

SUBTOPIC: **PERIPHERAL ARTERIAL DISEASE**

SUBTOPIC: **PROPHYLACTIC AMPUTATION** | **RECONSTRUCTION**

SUBTOPIC: **WOUND HEALING**

ESTIMATED TIME TO COMPLETE: 1 hr

Semmelweis University  
<http://semmelweis.hu>

Screening and management  
of diabetes mellitus in primary care

Dr. Bernádettk Márkus  
Assistant lecturer,  
General Practitioner

Empower e-Learning platform to expand the reach of EASD's educational goal to disseminate knowledge and proficiency in diabetes research and care worldwide. You can access for free! Try it!





#### AIM

To educate, inform and engage healthcare professionals around the world by addressing standard themes in practical diabetology as well as novel and complex themes in modern diabetology that overlap with other medical disciplines.

#### FORMAT

Comprehensive online courses divided into a series of modules which have been built and reviewed with experts from around the world and provide case based online education with engaging interactive multi-media content including expert videos, audios, animations and more.

# EASD e-learning courses

EASD e-Learning

Virtual Consultation Room

---

## Meet Wasim



Patient information	Current medication
<ul style="list-style-type: none"> <li>• Occupation: teacher</li> <li>• Age: 58 years old</li> <li>• Height: 178 cm</li> <li>• Weight: 100 kg</li> <li>• Sedentary life-style</li> <li>• Diagnosed of T2DM 8 years ago</li> <li>• Overweight</li> <li>• Weight gain from current antidiabetic treatment</li> </ul> <p><b>Blood pressure:</b></p> <ul style="list-style-type: none"> <li>• 150/100 mmHg</li> </ul> <p><b>BMI:</b></p> <ul style="list-style-type: none"> <li>• 34.4 kg/m<sup>2</sup></li> </ul>	<ul style="list-style-type: none"> <li>• HbA1c: 8.4%</li> <li>• FPG: 6.1-6.7 mmol/L (110-120 mg/dL)</li> <li>• PPQ: 9.4-10.0 mmol/L (170-180 mg/dL)</li> <li>• HDL cholesterol: 0.9 mmol/L (35 mg/dL)</li> <li>• LDL cholesterol: 2.6 mmol/L (99 mg/dL)</li> <li>• Triglycerides: 2.0 mmol/L (180 mg/dL)</li> <li>• eGFR: 60 mL/min/1.73 m<sup>2</sup></li> </ul>
<ul style="list-style-type: none"> <li>• Antihypertensive therapy               <ul style="list-style-type: none"> <li>- Metoprolol 100 mg BID</li> <li>- Candesartan 16 mg QD</li> </ul> </li> <li>• Concomitant medications               <ul style="list-style-type: none"> <li>- Atorvastatin 20 mg QD</li> </ul> </li> </ul>	



Semmelweis University  
<http://semmelweis.hu>

Screening and management  
of diabetes mellitus in primary care

Dr. Bernadett Márkus  
Assistant Lecturer,  
General Practitioner

Virtual Patients

# EASD e-learning courses

EASD e-Learning

Virtual Consultation Room

Question 1 of 1

What is the preferred next step?



- Add 10U insulin glargine
- Revisit the personalised management plan with the patient and discuss targets
- Advise lifestyle coaching
- Add a SGLT2i
- Refer to a dietician



Answer question then click anywhere to continue

Submit



Semmelweis University  
<http://semmelweis.hu>

Screening and management  
of diabetes mellitus in primary care

Dr. Bernadett Márkus  
Assistant lecturer,  
General Practitioner

# EASD e-learning courses

**EASD e-Learning**

Virtual Consultation Room

Question 1 of 1

**What is the preferred next step?**



- Add 10U insulin glargine
- Revisit the personalised management plan with the patient and discuss targets
- Advise lifestyle coaching
- Add a SGLT2i
- Refer to a dietician

**Correct**

Answer question then click anywhere to continue

  Semmelweis University  
<http://semmelweis.hu>

Screening and management  
of diabetes mellitus in primary care

Dr. Bernádeti Márkus  
Assistant lecturer,  
General Practitioner

# EASD e-learning courses

EASD e-Learning

Virtual Consultation Room

How would you alter the glucose-lowering therapy of the patient?



- Add a SGLT2i
- Replace the sulphonylureum
- It depends
- Add a TZD
- Add 10U insulin glargine
- Add a DPP4i
- Add a GLP1 RA



**Incorrect**

Answer question then click anywhere to continue



Semmelweis University  
<http://semmelweis.hu>

Screening and management  
of diabetes mellitus in primary care

Dr. Bernádeti Márkus  
Assistant lecturer,  
General Practitioner

# EASD e-learning courses

EASD e-Learning

Virtual Consultation Room

Wasim



## Discussion points

- Replace the sulphonylurea: yes, because of hypo risk, but what to use them? He has a good life expectancy, thus 8.4% is too high. Each individual glucose lowering agent will provide a drop of 1-1.5% maximum, so will have little chance to achieve goal (HbA1c 7%).
- Add TRU insulin glargine: yes, but weight gain, more risk of hypoglycaemia - not first choice; if he would have symptoms of polyuria and polydipsia, then insulin is the preferred addition therapy.
- Add a SGLT2: yes, but be careful for bringing out hypo risk with SU - may need down tapering of SU.
- Add a DPP4i: odds of reaching 7% are small, not preferred choice.
- Add a TZD: low drop, TZD is an option, but beware of fluid retention and weight gain.
- Add a GLP1 RA: this is the preferred choice when an injectable is considered and it can be considered at 8.4% - advantage is weight loss, but may require down tapering of SU or hypoglycaemia risk - however, it depends whether the patient wants to inject.



Semmelweis University  
<http://semmelweis.hu>

Screening and management  
of diabetes mellitus in primary care

Dr Bernádet Mária  
Assistant Lecturer,  
General Practitioner

## Meet Eva



### Patient information

- Occupation: Bookkeeper
- Age: 52 years old
- Height: 165 cm
- Weight: 78 kg
- Diagnosed with T2DM 8 months ago at occasion of myocardial infarction
- Recently ex-smoker

### Blood pressure:

- 145/90 mmHg

### BMI:

- 29.0 kg/m<sup>2</sup>

- HbA1c: 8.0%
- FPG: 8.0-9.1 mmol/L (144-163 mg/dL)
- PPQ: 12.5-13.5 mmol/L (225-243 mg/dL)
- HDL cholesterol: 0.9 mmol/L (36 mg/dL)
- LDL cholesterol: 2.3 mmol/L (89 mg/dL)
- Triglycerides: 4.2 mmol/L (370 mg/dL)
- eGFR: 65 mL/min/1.73 m<sup>2</sup>

### Current medication


- Antidiabetic therapy
  - Metformin 1000 mg QD
  - Glimepiride 4 mg QD
  - Insulin 40 mg QD
  - Enalapril 5mg QD




EASD e-Learning

Virtual Consultation Room Question 1 of 1



**What is the preferred next step?**



- Refer to a dietician
- Add a sulphonylureum
- Advise lifestyle coaching
- Revisit the personalised management plan with the patient and discuss targets
- Add 10U insulin glargine



Answer question then click anywhere to continue Submit



Semmelweis University  
<http://semmelweis.hu>

Screening and management  
of diabetes mellitus in primary care

Dr. Bernadett Márkus  
Assistant Lecturer,  
General Practitioner




EASD e-Learning

Virtual Consultation Room

Question 4 of 4

What would you suggest as a first add-on therapy to metformin in this patient?



- Add a sulphonylureum
- Add a TZD
- Add 10U insulin glargine
- Add a DPP4i
- Add a SGLT2i
- Add a GLP1 RA

Please select two answers

**Correct**

Answer question then click anywhere to continue

Semmelweis University  
<http://semmelweis.hu>

Screening and management  
of diabetes mellitus in primary care

Dr. Bernadett Márkus  
Assistant lecturer,  
General Practitioner

EASD e-Learning

Virtual Consultation Room

Under what conditions would you consider prescribing insulin for this patient?

If she had symptoms of catabolism (polyuria, polydipsia, weight loss, fatigue...)

Never



Answer question then click anywhere to continue

Semmelweis University  
<http://semmelweis.hu>

Screening and management  
of diabetes mellitus in primary care

Dr. Bernádeti Márkus  
Assistant lecturer,  
General Practitioner

How would you initiate insulin?



- 20U of premixed insulin in the morning
- 0.1U/kg of basal insulin once daily and uptitrate to fasting glycaemia
- Full basal bolus regimen
- 4U of basal insulin twice daily



Answer question then click anywhere to continue



How would you initiate insulin?



- 20U of premixed insulin in the morning
- 0.1U/kg of basal insulin once daily and uptitrate to fasting glycaemia
- Full basal bolus regimen
- 4U of basal insulin twice daily

Correct

Answer question then click anywhere to continue



Semmelweis University  
<http://semmelweis.hu>

Screening and management  
of diabetes mellitus in primary care

Dr. Bernadett Márkus  
Assistant Lecturer,  
General Practitioner

# EASD e-learning courses

EASD e-Learning

Virtual Consultation Room

## Meet Timothy



### Patient information

- Occupation: bus driver
- Age: 55 years old
- Height: 176cm
- Weight: 105 kg
- Type 2 diabetes for 3 years
- Family history of obesity
- Sedentary lifestyle due to nature of the job
- Episodes of hypoglycaemia
- HbA1c: 8.4%
- FPG: 7.2-7.4 mmol/L (129-133 mg/dL)
- PPQ: 11.9-12.1 mmol/L (214-218 mg/dL)
- HDL cholesterol: 1.3 mmol/L (52 mg/dL)
- LDL cholesterol: 2.6 mmol/L (99 mg/dL)
- Triglycerides: 1.7 mmol/L (150 mg/dL)
- eGFR: 115 mL/min/1.73 m<sup>2</sup>

### Blood pressure:

- 135/75 mmHg

### BMI:

- 34.4 kg/m<sup>2</sup>

### Current medication

- Antihyperglycaemic therapy
  - Metformin 1000 mg BID
- Cardiovascular medications
  - Atorvastatin 20 mg QD



Semmelweis University  
<http://semmelweis.hu>

Screening and management  
of diabetes mellitus in primary care

Dr. Bernádet Mária  
Assistant Lecturer,  
General Practitioner

# EASD e-learning courses

EASD e-Learning

Virtual Consultation Room

Question 3 of 7

What is the preferred next step?



- Add a sulphonylureum
- Add 10U insulin glargine
- Revisit the personalised management plan with the patient and discuss targets
- Advise lifestyle coaching
- Refer to a dietician

Answer question then click anywhere to continue

Submit



Semmelweis University  
<http://semmelweis.hu>

Screening and management  
of diabetes mellitus in primary care

Dr. Bernádeti Márkus  
Assistant lecturer,  
General Practitioner

# EASD e-learning courses

EASD e-Learning

Virtual Consultation Room

Question 3 of 4

Would you change the first add-on therapy to metformin in this patient?



- Add a DPP4i
- Add a sulphonylureum
- Add a TZD
- There is no right answer
- Add 10U insulin glargine
- Add a SGLT2i



Answer question then click anywhere to continue

Submit



Semmelweis University  
<http://semmelweis.hu>

Screening and management  
of diabetes mellitus in primary care

Dr. Bernadett Márkus  
Assistant lecturer,  
General Practitioner

# EASD e-learning courses

EASD e-Learning

Virtual Consultation Room

Question 1/11

Would you change the first add-on therapy to metformin in this patient?



- Add a DPP4i
- Add a sulphonylureum
- Add a TZD
- There is no right answer
- Add 10U insulin glargine
- Add a SGLT2i



Correct

Answer question then click anywhere to continue

Submit



Semmelweis University  
<http://semmelweis.hu>

Screening and management  
of diabetes mellitus in primary care

Dr. Bernadett Márkus  
Assistant lecturer,  
General Practitioner



EASD e-Learning



Virtual Consultation Room

Question 10

Would your choice of first add-on therapy to metformin differ if the patient's HbA1c was >9.5%?

No

Yes, if he had symptoms of catabolism (polyuria, polydipsia, weight loss, fatigue...)



Answer question then click anywhere to continue

Submit

Semmelweis University  
<http://semmelweis.hu>

Screening and management  
of diabetes mellitus in primary care

Dr. Bernadett Márkus  
Assistant lecturer,  
General Practitioner

# EASD e-learning courses

EASD e-Learning

Virtual Consultation Room

Timothy



#### Discussion points

- Would you change the first add-on therapy to metformin in this patient?
- What effects, if any, would you expect on HbA1c and other metabolic parameters in this patient?
- Would your choice of first add-on therapy to metformin differ if the patient's HbA1c was  $\geq 9.0\%$ ?
- Would your choice of first add-on therapy to metformin differ if the patient had a history of CV disease?
- If the patient's HbA1c was not adequately controlled with dual anti-diabetes therapy, what would be your preferred second add-on therapy?
- What would be your first choice of injectable therapy in this patient?
- Under what conditions would you consider prescribing insulin for this patient?
- Does the treatment strategy for this patient differ to what is recommended by clinical guidelines? If so, how?



Semmelweis University  
<http://semmelweis.hu>

Screening and management  
of diabetes mellitus in primary care

Dr. Bernádeti Márkus  
Assistant Lecturer,  
General Practitioner

## ADDITIONAL RESOURCES

- ↗ American Diabetes Association - **Standards of Medical Care in Diabetes**—2019. <https://doi.org/10.2337/cd18-0105>
- ↗ **Management of hyperglycaemia in type 2 diabetes**, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). *Diabetologia*. <https://doi.org/10.1007/s00125-018-4729-5>
- ↗ Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2019 American Diabetes Association *Diabetes Care* 2019 Jan; 42(Supplement 1): S13-S28. <https://doi.org/10.2337/dc19-S002>
- ↗ EASD E-Learning: <https://elearning.easd.org/>
- ↗ International Diabetes Federation <https://idf.org/>



Semmelweis University  
<http://semmelweis.hu>

Screening and management  
of diabetes mellitus in primary care

Dr. Bernádeti Márkus  
Assistant lecturer,  
General Practitioner

**Thank you for  
your attention!**



Dr. Bernadett Márkus  
markus.bernadett@med.semmelweis-univ.hu



Semmelweis University  
<http://semmelweis.hu>

Screening and management  
of diabetes mellitus in primary care

Dr. Bernadett Márkus  
Assistant lecturer,  
General Practitioner